FTH Stock — Faeth Therapeutics Inc.: Cash, EV, Pipeline

Share price

$34.50

Market cap

$891.5M

Cash

$186.4M

Enterprise value

$705.1M

Balance sheet

Cash	$186.4M
Debt	$0.0M
Net cash	$186.4M
Enterprise value	$705.1M
Basic shares	25.8M shares
Fully diluted shares	31.9M shares
Fully diluted market cap	$1,101.1M
Cash per share	$7.22

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading FTH daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Oct 13 - Nov 24	Sapanisertib	Phase 2	Endometrial Cancer	—
Jun 12 - Jul 24	Serabelisib	Phase 1/2	HR+ HER2- Breast Cancer	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

PIKTOR

Phase 2 · Active Modality: oral multi-node inhibitor

Target PI3K/AKT/mTOR pathway

Partnerships Takeda (agreement; Phase 3 first-dosing equity issuance provision renegotiated and removed in January 2026)

Indications

second-line advanced endometrial cancer (Stage not disclosed)
HR+/HER2- advanced breast cancer (Stage not disclosed)

Catalysts

— None
— None
— None

Status note Lead program following the February 2026 Faeth acquisition (all-oral combination of serabelisib and sapanisertib). First patient dosed in FTH-PIK-101 in April 2026. NEAAR and IEM preclinical programs noted but unnamed as candidates.

solnerstotug

Phase 1 · Active Modality: conditionally active monoclonal antibody

Aliases SNS-101

Target VISTA

Indications

not disclosed (Stage not disclosed)

Status note Legacy program. Company is completing the remaining portion of the Phase 1/2 trial with patients currently on study; no new development plans stated.

Per-asset detail extracted from the 10-Q filed 2026-08-04. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Sapanisertib
Lead indication	Endometrial Cancer
Lead phase	Phase 2
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06463028	Phase 2	Recruiting	Sponsor	Faeth Therapeutics	—	Endometrial Cancer	—
NCT07558733	Phase 1/2	Recruiting	Sponsor	Faeth Therapeutics	—	HR+ HER2- Breast Cancer	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Faeth Therapeutics on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Baker Bros. Advisors	1,286,411	+1,286,411	0.16%	2026-08-14
Logos Global Management	722,020	+692,020	0.78%	2026-08-14
ADAR1 Capital Management	361,010	+361,010	0.42%	2026-08-14
Ikarian Capital	35,386	+29,035	0.14%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

FTH — Faeth Therapeutics Inc.